What were the key takeaways from Ginkgo Bioworks’s earnings call?

What guidance did Ginkgo Bioworks's management provide for the next earnings period?

What is Ginkgo Bioworks's latest dividend and current dividend yield?

What were the key takeaways from Ginkgo Bioworks's earnings call?

Did Ginkgo Bioworks beat or miss consensus estimates last quarter?

What does Ginkgo Bioworks do and what are its main business segments?

What is the revenue and EPS growth rate for Ginkgo Bioworks year over year?

What factors drove the changes in Ginkgo Bioworks's revenue and profit?

- **Autonomous Lab Expansion**: 2026 focus on scaling to 100 racks, with $47M DOE deal and cloud lab services driving growth. 
- **Cost Efficiency**: Cash burn reduced 55% to $171M in FY25, 2026 guidance of $125M-$150M reflects disciplined investment.
- **AI Integration Success**: OpenAI collaboration achieved 40% better results, showcasing AI-driven lab automation potential.
- **Biosecurity Spin-Off**: Divestiture enables focus on core autonomous lab strategy while retaining upside through minority stake.
- **Manufacturing Tailwinds**: Interest in QC automation in pharma manufacturing, aligning with U.S. onshoring trends.

**【CEO Summary Section】**
- **Autonomous Lab Focus**: CEO Jason Kelly emphasized 2026 as the year to invest in autonomous labs, with plans to expand from 50 to 100 racks in Boston. The goal is to replace traditional lab benches with automated systems, reducing costs and increasing research productivity.
- **Biosecurity Divestiture**: The biosecurity business was spun off to focus capital on autonomous labs. Ginkgo retains a minority stake, allowing it to benefit from the spin-off while reducing operational complexity.
- **Cost Efficiency**: Cash burn reduced from $383M in FY24 to $171M in FY25, with 2026 guidance of $125M-$150M. This reflects disciplined spending and restructuring efforts.
- **Strategic Partnerships**: Announced a $47M contract with DOE for a 97-rack lab at Pacific Northwest National Labs, showcasing government interest in autonomous labs.
- **AI Integration**: Demonstrated AI-driven experiments with OpenAI, achieving 40% better results in cell-free protein synthesis, highlighting the potential of AI in lab automation.

**【CFO Financial Commentary】**
- **Revenue Performance**: Cell Engineering revenue decreased 26% Q4/Q4 to $26M, driven by program rationalization. Full-year 2025 revenue was $133M, down 24% from 2024. Biosecurity revenue was $37M annually.
- **Expense Reduction**: R&D expenses fell 42% to $159M in FY25, G&A decreased 51% to $56M. Resetting a cloud partnership with Google reduced future commitments by $100M.
- **Cash Position**: Ended FY25 with $430M in cash, enabling focused investment in autonomous labs while maintaining a strong cash margin of safety.
- **Guidance Shift**: 2026 will not provide revenue guidance, focusing instead on cash burn as a metric to reflect service continuity and investment balance.

**【Q&A Highlights】**
- **Revenue Growth Potential**: Expansion to 100 racks in H1 2026 could drive repeat business through cloud lab services, datapoints, and system sales. Customers like DOE and pharma companies are prioritizing autonomous lab adoption.
- **Manufacturing Tailwinds**: Interest in using racks for QC in manufacturing facilities, leveraging high-throughput capabilities for post-clinical drug monitoring.
- **Datapoints Reception**: Strong demand for large datasets for bio-AI training, with 10 top pharma customers using the service. This aligns with industry trends of AI-driven drug discovery.
- **Scalability Strategies**: Current manufacturing processes are efficient, but plans to partner for larger-scale production as demand grows. Design-for-manufacturability improvements have reduced component complexity.


Ginkgo Bioworks Holdings, Inc.(DNA)-20260227-2025 Q4 Earnings call transcript

- **AI Lab Automation**: Ginkgo's RAC system enables AI models to control lab experiments via standardized robotics.
- **Government Growth**: 20%+ revenue from U.S. grants, $22M BARDA award for antibody manufacturing.
- **Cash Efficiency**: Q3 2025 cash burn $28M (-75% YoY), $462M cash with no debt.
- **Future Labs Partnership**: Collaborating with FutureHouse to develop AI scientists that design and execute experiments.

**【Management Opening Remarks】**
- CEO Jason Kelly highlighted three strategic objectives: delivering autonomous lab robotics, expanding the Boston RAC lab, and offering frontier AI-driven biotech services.
- CFO Steve Coen reported a strong cash position of $462M with no debt, down 75% YoY in cash burn due to restructuring.

**【CEO Strategic Vision】**
- **AI & Automation Integration**: Ginkgo's RAC (reconfigurable automation carts) enable AI models to control lab experiments via standardized, plug-and-play robotics.
- **Government & Pharma Expansion**: Won $22M BARDA contract for antibody manufacturing and partnered with Bayer for microbial fertilizers.
- **Future Labs Collaboration**: Partnered with FutureHouse to develop AI models that design and execute experiments using Ginkgo's automation.

**【CFO Financial Update】**
- **Revenue Decline**: Cell Engineering revenue $29M (-61% YoY), Biosecurity $9M (19% margin).
- **Cost Efficiency**: G&A expenses down 47%, R&D down 8%, net loss $56M (-140% YoY).
- **Cash Management**: Q3 2025 cash burn $28M vs. $114M prior year, driven by program rationalization.

**【Q&A Highlights】**
- **Government Exposure**: 20%+ revenue from U.S. grants, unaffected by shutdown.
- **RAC Rollout**: Target 100+ RACs in Boston lab by end-2026, demoing protein expression protocols.
- **2030 Vision**: 80% tools (robotics, AI) vs. 20% services; biosecurity could grow if CDC adopts monitoring tech.
- **Google Reset**: Reduced cloud commitment by $100M, extended term to 6 years to align with slower bio-AI adoption.

Ginkgo Bioworks Holdings, Inc.(DNA)-20251107-2025 Q3 Earnings call transcript

- **Cost Efficiency Milestone**: Achieved $250M annual cost savings 3 months early, reducing cash burn by 65% YoY
- **Strategic Automation Push**: RAC system now integrates 50+ lab instruments, with ADME reagent kit generating 100+ sample requests
- **Financial Resilience**: $474M cash balance with no debt provides buffer for 2026 growth
- **Biosecurity Caution**: International market softness leading to conservative $40M+ annual guidance
- **Key Growth Driver**: Automation adoption rate critical to achieving adjusted EBITDA breakeven by end-2026

**【CEO Summary Section】**
- Achieved $250M annual run rate cost savings 3 months early, reducing cash burn to $38M Q2 2025 vs $110M prior year. 
- $474M cash balance with no debt provides strategic flexibility for 2026 growth initiatives.
- Shift to life science tools: 
  - Automation RAC system now supports 50+ lab instruments, enabling high-mix/high-throughput protocols
  - Launched ADME reagent kit at $2,000/10ml, with 100+ sample requests in first week
  - Datapoints CRO services now offer ADME, antibody developability, and perturbation profiling
- Automation vision: General-purpose lab automation platform to replace manual lab benches

**【CFO Financial Commentary】**
- Q2 2025 Results:
  - Total revenue $167M (Cell Engineering $39M, Biosecurity $10M)
  - Adjusted EBITDA -$28M (vs -$99M prior year)
  - Cash burn $38M (vs $110M prior year)
  - Segment gross margin: Cell Engineering 18%, Biosecurity 18%
- Key improvements:
  - Cell Engineering R&D down 63%, G&A down 57%
  - Excess lease costs $12M (base rent on unused space)
- 2025 Guidance: $167-187M total revenue

**【Q&A Key Highlights】**
- **Automation Growth**: CEO sees potential for automation to become majority of revenue if achieves lab bench-like generality
- **Acquisition Strategy**: No near-term plans, but open to strategic fits
- **Biosecurity Risks**: International market softness, conservative guidance of $40M+ annual revenue
- **EBITDA Levers**: 
  - Cost savings from $250M run rate (6 quarters remaining)
  - Revenue growth from tools (automation, reagents)
  - Sublease progress on $12M excess space

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript

- **Cost Efficiency Record**: $205M annualized cost savings exceed 2026 breakeven target, maintaining $517M cash buffer.
- **Government Momentum**: $29M ARPA-H win highlights biosecurity/onshoring focus; 28 gov projects with $180M+ potential.
- **Tools Breakthrough**: First diagnostics automation deal; Datapoints data sets drive new customer engagement. Tools revenue guide at low-double-digit M for 2025.

**【CEO Key Initiatives】**
- **Cost Reduction Progress**: Achieved $205M annualized run rate reduction, exceeding $200M target for 2026 EBITDA breakeven. Current cash balance of $517M with no debt.
- **Government Contracts**: 28 active projects with $180M+ potential, including $29M ARPA-H WHEAT program for onshore drug manufacturing.
- **Tools Expansion**: Datapoints launched new data sets (e.g., 246 therapeutic antibodies), Automation secured first diagnostics deal with Aura Genetics.

**【CFO Financial Highlights】**
- **Cell Engineering**: Q1 revenue $38M (+37% YoY), 123 revenue-generating programs (+32% YoY). Adjusted EBITDA improved 60% YoY.
- **Biosecurity**: $10M revenue, 28% gross margin. Adjusted EBITDA improved 80% YoY.
- **Cash Management**: Q1 cash burn $58M vs. $104M YoY. Full-year 2025 revenue guidance updated to $167-187M.

**【Q&A Key Takeaways】**
- **Government Funding Risk**: Biotech remains a priority; ARPA-H contracts are non-DOGE funded. Biosecurity programs may achieve breakeven in 2025.
- **Tools Growth**: Datapoints sees low-single-digit M contributions in Q1, automation sales cycle 6-12 months. Tools revenue guide conservative at low-double-digit M for 2025.
- **Macroeconomic Impact**: Pharma R&D outsourcing cautious, but tools business (fee-for-service) resilient with smaller deal sizes.

Ginkgo Bioworks (DNA)-6 May 25-2025 Q1 Earnings call transcript

- **Cost control success**: Q4 cash burn reduced to $55M (down 51% vs. Q3), with $190M annualized OpEx cuts. 
- **Tools business momentum**: 7 new contracts in Q4 for data points/automation, targeting AI-driven R&D. 
- **Biosecurity pivot**: Shifting from COVID testing to EU disease surveillance ($24M project), though 2025 guidance cautious on gov funding. 
- **2026 EBITDA path**: $60M OpEx reduction + tools growth + sublease income needed to offset $65M excess space costs. 
- **Liquidity strength**: $562M cash with no debt, providing flexibility in uncertain biotech R&D market.

**【CEO Summary Section】**
- Ginkgo achieved a 29% year-over-year increase in Cell Engineering revenue to $35 million in Q4 2024, driven by large biopharma and government customers. 
- The company reduced annualized OpEx by $190 million through Q4, resulting in Q4 cash burn of $55 million (down 51% from Q3). 
- Launched new tools businesses (data points and automation) with 7 new customer contracts in Q4, targeting AI-driven R&D efficiency. 
- Announced a $24M EU Biosecurity project for disease surveillance infrastructure. 

**【CFO Financial Commentary】**
- Full year 2024 Cell Engineering revenue: $174M (down 10% YoY due to customer mix shift). 
- Q4 Biosecurity revenue: $9M (down 51% YoY from $108M in 2023). 
- Adjusted EBITDA improved to -$293M in 2024 (from -$365M in 2023), driven by cost cuts and milestone releases. 
- 2025 guidance: $160-180M total revenue, with Cell Engineering at $110-130M and Biosecurity at $50M+. 
- Cash position remains strong at $562M with no debt. 

**【Q&A Highlights】**
- 2025 tools business contribution: $10-20M (conservative) vs. potential upside from pipeline. 
- Path to 2026 EBITDA breakeven: $60M annual OpEx reduction, revenue growth, and sublease mitigation of $65M excess space costs. 
- Biosecurity risk: 2025 guidance assumes no changes to government contracts, but EU program provides diversification. 
- Automation adoption: Rack systems sold to pharma startups with 7x throughput gains, targeting modular lab infrastructure. 
- Downstream value share: $1.7B in potential milestones, but no reliance in 2026 breakeven plan.

Actual	-3.2	-44	-14.8	-16.4	-16.4	-4	-4.4	-3.6	-6.4	-4.4	-3.2	-4.4	-1.08	-2	-1.68	-1.1	-1.45	-1.41
Forecast	-1.4	-1.6571	-8.5616	-7.3264	-10.4667	-8.3251	-3.3995	-3.45	-3.6571	-3.8667	-3.3333	-3.0976	-2.7282	-1.504	-1.5336	-1.5667	-1.2413	-1.455
Surprise	-128.57%	-2555.24%	-72.86%	-123.85%	-56.69%	+51.95%	-29.43%	-4.35%	-75.00%	-13.79%	+4.00%	-42.05%	+60.41%	-32.98%	-9.55%	+29.79%	-16.81%	+3.09%

DNA

DNA fundamentals

DNA Q4 2025 Earnings

Earnings Call

You can ask Aime

DNA

DNA fundamentals

DNA Q4 2025 Earnings

Earnings Call

DNA Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

DNA Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

DNA Earnings Call Summary for Q2/20255:30 PM on Aug 7, 2025

DNA Earnings Call Summary for Q1/20255:30 PM on May 6, 2025

DNA Earnings Call Summary for Q4/20245:30 PM on Feb 25, 2025

You can ask Aime